AZNAstraZenecaRunning, no new patients
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Untreated Chronic Lymphocytic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 155 (final count)
- Started
- Jan 20, 2020
- Main results expected
- Jan 3, 2024
- Fully finished
- Jan 1, 2027
- Results posted
- Jan 30, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) Assessed by BICR
Measured over: Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04075292 · record last updated 2026-09-14 · checked 2026-11-09 15:47 UTC